急性心肌梗死合并心源性休克患者的血运重建治疗研究进展  

Research progress of revascularization therapy in patients with acute myocardial infarction and cardiogenic shock

作　　者：王心宇 乔树宾 WANG Xin-yu;QIAO Shu-bin(Coronary Heart Disease Center,National Center for Cardiovascular Disease and Fuwai Hospital,China Academy of Medical Science and Peking Union Medical College,Beijing 100037,China)

机构地区：[1]中国医学科学院阜外医院冠心病中心,北京市100037

出　　处：《中国心血管病研究》2021年第4期371-376,共6页Chinese Journal of Cardiovascular Research

摘　　要：心源性休克是急性心肌梗死患者最严重的并发症。虽然已有多种药物治疗、综合的监护管理以及先进的器械辅助,但急性心肌梗死合并心源性休克患者依旧保持着较高的病死率。多项研究表明,尽早进行血运重建治疗是目前唯一可以明显改善急性心肌梗死合并心源性休克患者预后的治疗措施。因此尽早进行血运重建治疗是急性心肌梗死合并心源性休克患者治疗中最重要的一环。本文现对其研究进展进行综述。Cardiogenic shock is the most serious complication in patients with acute myocardial infarction.Although there are multiple drug treatments, comprehensive monitoring and management and advanced device assistance, the mortality of patients with acute myocardial infarction and cardiogenic shock is still higher. A number of studies have shown that as early as possible revascularizing therapy is the only treatment that can significantly improve the prognosis of patients with acute myocardial infarction and cardiogenic shock. Therefore,early revascularization treatment is the most important part of the treatment of patients with acute myocardial infarction and cardiogenic shock. This article reviews the research progress.

关 键 词：急性心肌梗死 心源性休克 血运重建治疗 

分 类 号：R542.22[医药卫生—心血管疾病]